How It Works
What is this blood test based on?
The ONCOblot® blood test identifies a specific type of protein in the blood, ENOX2, which exists only on the surface of a malignant cancer cell. The ENOX2 proteins are shed into the circulation and can be detected in the blood. These proteins serve as highly sensitive markers for confirmation of cancer presence. The test is a valuable complement to early intervention.
How sensitive is this blood test?
The ONCOblot® Test has been shown to detect cancer as early as Stage 0. The limit of detection is an estimated 2 million cells (1.2 mm cancer, roughly the size of a pinhead) compared to several trillion cells (7 mm diameter) for a positive mammogram.
How does this blood test determine organ site?
The ONCOblot® Test uses techniques known as two-dimensional gel electrophoresis and western blot analysis along with an ENOX2 protein-specific antibody for detection. The result of the blood test is presented visually on the ONCOblot®. Each type of ENOX2 has a specific location (molecular weight and isoelectric point) on the blot to demonstrate ENOX2 presence and to identify the tissue of origin.
In the example below, the circled spot indicates a lung cancer-specific ENOX2 protein. (The two spots labeled R are references used for calibration.)
What are the steps involved for the ONCOblot® Test?
• Test kit delivered to physician (must be ordered by a physician)
• Blood draw and test kit completed and sent to ONCOblot® Labs
• Approximately 15 business days for completion
• Results sent to physician
How is the ONCOblot® Test being used?
• Versatile addition to other cancer tests
(such as high PSA, abnormal mammogram, suspicious PET scan)
• Confirms biopsy results
• Detects cancer in high risk populations
• Confirms post treatment effectiveness
Laboratory-Developed Test (LDT)
ONCOblot® is a laboratory developed, CLIA Certified, CAP Accredited, blood serum test that meets current FDA guidelines. A 510(k) submission to the FDA is in progress as well as plans to seek insurance coverage.